| First Author | Chen YH | Year | 2015 |
| Journal | Cell Rep | Volume | 10 |
| Issue | 11 | Pages | 1899-912 |
| PubMed ID | 25772366 | Mgi Jnum | J:228181 |
| Mgi Id | MGI:5705469 | Doi | 10.1016/j.celrep.2015.02.041 |
| Citation | Chen YH, et al. (2015) Mouse low-grade gliomas contain cancer stem cells with unique molecular and functional properties. Cell Rep 10(11):1899-912 |
| abstractText | The availability of adult malignant glioma stem cells (GSCs) has provided unprecedented opportunities to identify the mechanisms underlying treatment resistance. Unfortunately, there is a lack of comparable reagents for the study of pediatric low-grade glioma (LGG). Leveraging a neurofibromatosis 1 (Nf1) genetically engineered mouse LGG model, we report the isolation of CD133(+) multi-potent low-grade glioma stem cells (LG-GSCs), which generate glioma-like lesions histologically similar to the parent tumor following injection into immunocompetent hosts. In addition, we demonstrate that these LG-GSCs harbor selective resistance to currently employed conventional and biologically targeted anti-cancer agents, which reflect the acquisition of new targetable signaling pathway abnormalities. Using transcriptomic analysis to identify additional molecular properties, we discovered that mouse and human LG-GSCs harbor high levels of Abcg1 expression critical for protecting against ER-stress-induced mouse LG-GSC apoptosis. Collectively, these findings establish that LGG cancer stem cells have unique molecular and functional properties relevant to brain cancer treatment. |
